Tourmaline Bio, Inc. - Common Stock TRML 深 沪
等待开盘 09-06 09:30:00 美东时间
27.455
+2.355
+9.38%
华盛通- 最 高28.455
- 今 开25.80
- 成交量 28.83万股
- 最 低 25.73
- 昨 收 25.10
- 总市值 7.05亿
- 52周最高 29.7883
- 市盈率 静 --
- 换手率 1.12%
- 52周最低 11.56
- 委 比 -98.51%
- 总股本 2569.23万
- 历史最高 183.082
- 量 比 2.14
- 振 幅 10.86%
- 历史最低 -6.218
- 每 手 1
- 风险率 8.89%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Tourmaline Bio Presents Data from the Ongoing Phase 2 TRANQUILITY Trial at the 2025 European Society of Cardiology Congress
Tourmaline Bio's Phase 2 TRANQUILITY trial shows pacibekitug, a long-acting IL-6 inhibitor, consistently reduces high-sensitivity C-reactive protein (hs-CRP) across diverse subgroups, including sex, BMI, diabetes status, and baseline hs-CRP levels. The drug also significantly lowers secondary biomarkers like lipoprotein(a), fibrinogen, and serum amyloid A. With quarterly dosing, pacibekitug achieved over 85% hs-CRP reduction, making it the first ...
08-31 14:23
美股大行评级 | 潜在涨幅仍有782.74%！Passage BIO遭Canaccord Genuity下调目标价至67美元，维持"买入"评级
今日重点评级关注：Northland Capital Markets：维持BrainsWay"跑赢大市"评级，目标价从15美元升至19美元；Lake Street：维持Hyperfine"买入"评级，目标价从1.5美元升至2美元
08-15 09:30
Guggenheim Reiterates Buy on Tourmaline Bio, Maintains $55 Price Target
Guggenheim analyst Yatin Suneja reiterates Tourmaline Bio (NASDAQ:TRML) with a Buy and maintains $55 price target.
08-14 21:46
Tourmaline Bio Reports Second Quarter 2025 Financial Results and Recent Business Highlights
Tourmaline Bio reported positive topline results from its Phase 2 TRANQUILITY trial, demonstrating rapid and durable reductions in high-sensitivity C-reactive protein with quarterly dosing of pacibekitug. Additional data from the trial will be presented at the European Society of Cardiology Congress in August 2025. The company also plans to initiate a Phase 2 proof-of-concept trial for abdominal aortic aneurysm in late 2025 and is preparing for a...
08-13 11:00
新浪财经ESG：TRML MSCI（明晟）ESG评级调降至BBB
新浪财经ESG评级中心提供包括资讯、报告、培训、咨询等在内的14项ESG服务，助力上市公司传播ESG理念，提升ESG可持续发展表现。点击查看【 ESG评级中...
06-24 07:00
Tourmaline Bio Releases Updated Corporate Presentation
Tourmaline Bio ( ($TRML) ) has provided an announcement. On June 9, 2025, Tourm...
06-09 20:29
Trip.com Posts Weak Earnings, Joins Vipshop, Viking Holdings And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session
U.S. stock futures were mixed this morning, with the Nasdaq futures falling aro...
05-20 20:23
Tourmaline Bio posts mid-stage data for anti-inflammatory agent
Shares of Tourmaline Bio (NASDAQ:TRML) fell in the premarket on Tuesday after the company posted topline data from a mid-stage trial for its lead candidate, pacibekitug, in patients with elevated high...
05-20 20:17
Talaris Therapeutics GAAP EPS of -$0.89
Talaris Therapeutics press release (NASDAQ:TRML): Q1 GAAP EPS of -$0.89. – Cash, cash equivalents, and investments of $275.3 million as of March 31, 2025 provide expected cash runway into the second h...
05-02 22:25
美股大行评级 | 潜在涨幅38%！花旗：首予通用汽车(GM)"买入"评级，目标价62美元
<span> <meta content="no-referrer" name="referrer"></span><p>https://static-hk.hstong.com/public/forum-v2/status/icon/50267976/originalpic/1122085978711785472.png</p><span style="color:#999999;">编者按：每日追踪华尔街最新评级与目标价，挖掘潜力股投资机会。</span><blockquote> <p><span style="color:#fa1432;"><strong>今日重点评级关注</strong></span></p></blockquote><p>• Piper Sandler：维持Devon Energy(DVN)"超配"评级，目标价从54美元升至56美元</p> <p>• HC Wainwright & Co.：上调Dogwood Therapeutics(
04-24 09:56
